Welcome to ev3 Investor Relations

Since our founding in 2000, ev3 has been dedicated to developing innovative, breakthrough and clinically proven technologies and solutions for the treatment of peripheral vascular and neurovascular diseases, a strategy that we believe is uncommon in the medical device industry. Our products are used by endovascular specialists to treat a wide range of peripheral vascular and neurovascular diseases and disorders. We offer a comprehensive portfolio of treatment options, including the primary interventional technologies used today – peripheral angioplasty balloons, stents, plaque excision systems, embolic protection devices, liquid embolics, embMore >>

Recent News

• Press Releases by Date

ev3 Inc. Agrees to Settle Stockholder Litigation - 07/06/10

PLYMOUTH, Minn., Jul 6, 2010 (GlobeNewswire via COMTEX) --ev3 Inc. (Nasdaq:EVVV), a global endovascular device company, today announced that it has reached an agreement with the plaintiffs to settle the claims asserted in the purported stockholder class action lawsuits related to Covidien's proposed... More >>

ev3 Announces Acceptance of Pipeline(TM) Embolization Device - 06/21/10

PMA Application for Review by FDA PLYMOUTH, Minn., Jun 21, 2010 (GlobeNewswire via COMTEX) --ev3 Inc. (Nasdaq:EVVV), a global endovascular device company, today announced that the U.S. Food and Drug Administration (FDA) formally accepted for filing the company's Pre-Market Approval (PMA) applicati... More >>

Covidien Announces Definitive Agreement to Acquire ev3 Inc. - 06/01/10

Adds significant scale to vascular platform with strong market positions Provides broad product portfolio and robust pipeline in high-growth market segments Leverages global infrastructure, physician education and training expertise Dublin, Ireland and Plymouth, MN – June 1, 2010 – Covidien p... More >>

ev3 Inc. Files PMA Application for FDA Approval of Pipeline Embolization Device - 05/18/10

Premarket Approval Study Evaluates Use of Pipeline Embolization Device in Uncoilable or Failed Aneurysms PLYMOUTH, Minn., May 18, 2010 (GlobeNewswire via COMTEX) --ev3 Inc. (Nasdaq:EVVV), a global endovascular device company, today announced that it has filed the final module of its Premarket App... More >>

ev3 to Present at the 2010 Citi Investment Research Global Health Care Conference on May 27, 2010 - 05/17/10

PLYMOUTH, Minn., May 17, 2010 (GlobeNewswire via COMTEX) --ev3 Inc. (Nasdaq:EVVV) today announced that Shawn McCormick, senior vice president and chief financial officer, is scheduled to present at the 2010 Citi Investment Research Global Health Care Conference at 11:00 a.m. Eastern Time on Thursday... More >>

ev3 to Present at Baird's 2010 Growth Stock Conference on May 19, 2010 - 05/10/10

PLYMOUTH, Minn., May 10, 2010 (GlobeNewswire via COMTEX) --ev3 Inc. (Nasdaq:EVVV) today announced that Robert Palmisano, president and chief executive officer, is scheduled to present at Baird's 2010 Growth Stock Conference at 8:55 a.m. Central Time on Wednesday, May 19, 2010, at the Four Seasons Ho... More >>

ev3 to Present at the Bank of America Merrill Lynch Health Care Conference on May 11, 2010 - 05/04/10

PLYMOUTH, Minn., May 4, 2010 (GlobeNewswire via COMTEX) --ev3 Inc. (Nasdaq:EVVV) today announced that Robert Palmisano, president and chief executive officer, is scheduled to present at the Bank of America Merrill Lynch Health Care Conference at 2:20 p.m. Eastern Time on Tuesday, May 11, 2010, at th... More >>

ev3 Reports 2010 First Quarter Financial Results - 04/29/10

First Quarter Net Sales Increase 23% to $123.9 Million First Quarter GAAP EPS Increases to $0.09 Cash and Cash Equivalents Increase to $116.8 Million Full-Year 2010 Revenue and Earnings Guidance Increased PLYMOUTH, Minn., April 29, 2010 (... More >>

ev3 Inc. Announces Completion of Patient Enrollment in DURABILITY II Study - 04/26/10

Study to Evaluate Patency and Fracture Resistance of the EverFlex Self-Expanding Stent System for the Treatment of Peripheral Arterial Disease PLYMOUTH, Minn., Apr 26, 2010 (GlobeNewswire via COMTEX) --ev3 Inc. (Nasdaq:EVVV) today announced the completion of patient enrollment in the DURABILITY I... More >>

ev3 Inc. to Report 2010 First Quarter Results and Host Conference Call on April 29, 2010 - 04/22/10

PLYMOUTH, Minn., Apr 22, 2010 (GlobeNewswire via COMTEX) --ev3 Inc. (Nasdaq:EVVV) will release its 2010 first quarter financial results on Thursday, April 29, 2010, before regular market trading hours. The company will host a conference call and webcast the same day at 7:30 a.m. Central Time (8:3... More >>

Upcoming Events

• Full Calendar